Related Experiment Videos
[Modeling 5-FU clearance during a chronomodulated infusion].
F Kwiatkowski1, V Chevalier, R Chevrier
1Unité de recherche clinique, centre Jean-Perrin, 58, rue Montalembert, 63011 cedex, Clermont-Ferrand, France.
Pathologie-Biologie
|July 11, 2003
Summary
This study introduces a method for pharmacokinetic monitoring of chronomodulated chemotherapy. It helps manage drug levels and predict treatment response and toxicity in colorectal cancer patients receiving 5-fluorouracil.
Area of Science:
- Pharmacokinetics
- Oncology
- Drug Delivery Systems
Context:
- Continuous infusion chemotherapy is common, allowing dose adjustments.
- Chronotherapy, using timed drug release, complicates pharmacokinetic monitoring due to variable infusion rates.
- Metastatic colorectal cancer (mCRC) treatment often involves 5-fluorouracil (5-FU).
Purpose:
- To develop and validate a pharmacokinetic monitoring method for chronomodulated 5-fluorouracil (5-FU) and folinic acid infusions.
- To assess the feasibility of modulating drug delivery in chronotherapy.
- To correlate pharmacokinetic parameters with treatment outcomes in mCRC patients.
Summary:
- A pharmacokinetic follow-up method was developed and applied to 21 mCRC patients receiving chronomodulated 5-FU and folinic acid.
- The study enabled modeling of 5-FU clearance under chronomodulated infusion conditions.
- A novel index derived from pharmacokinetic data was found to correlate with treatment response and toxicity.
Impact:
- Provides a method for effective pharmacokinetic control in chronotherapy, enhancing drug safety and efficacy.
- Offers a predictive index for treatment response and toxicity in mCRC patients undergoing chronomodulated chemotherapy.
- Facilitates personalized cancer treatment by enabling dose adjustments based on individual drug metabolism.